Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S 81694 plus paclitaxel in metastatic breast cancer
NL-OMON46450Phase 2Completed
- Sponsor
- Servier
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of s 81694 and paclitaxel in breast cancer and triple-negative breast cancer (TNBC) (3 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose and 2 more. Started Nov 2017; status: completed.
02
Drugs
s 81694paclitaxel
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON46450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46450.